MedTrace Logo

Study to Learn More About the Stomach and Intestine Complaints of Children Aged From 3 to 14 Years

NCT04029376 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1032

Last updated 2019-09-19

No results posted yet for this study

Summary

In this observational study, researchers want to gain more information on children suffering from abnormal stomach and intestine function (based on the Rome criteria) and treated Iberogast. The Rome criteria have been developed by experts to support doctors to diagnose stomach and intestine disorders. This study will focus on children aged from 3 to 14 years in age treated by their doctor with the herbal drug Iberogast for their stomach and intestine complaints for one week. Researcher want to learn more about the efficacy of Iberogast by observing the changes of symptoms related to the stomach and intestine disorders. In addition information on the safety of the drug and how well the drug is tolerated by the patients will be collected.

Conditions

  • Functional Gastrointestinal Disorders

Interventions

DRUG

Iberogast®

The medication was applied 3 times 20 drops per day before or at meals with some liquid, ideally to one week insofar.

Sponsors & Collaborators

Eligibility

Min Age
3 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-01
Primary Completion
2008-10-01
Completion
2008-10-01

Countries

  • Germany

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04029376 on ClinicalTrials.gov